Premium
Continuous infusion 5‐fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid‐atlantic oncology program study
Author(s) -
Rothman Harvey,
Cantrell James E.,
Lokich Jacob,
Difino Santo,
Harvey Jimmie,
Ahlgren James,
Fryer John
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910715)68:2<264::aid-cncr2820680208>3.0.co;2-5
Subject(s) - medicine , fluorouracil , cisplatin , bolus (digestion) , adenocarcinoma , surgery , carcinoma , continuous infusion , pancreas , confidence interval , biopsy , chemotherapy , cancer
Fifty‐six previously untreated patients with biopsy‐proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5‐fluorouracil (5‐FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a 2‐week rest period. The objective response rate was 16% with two patients (4%) achieving a complete response (confidence intervals, 8% to 29%). The median survival time for all treated patients was 5.8 months; however, 26% of all patients were alive at 1 year. Both median survival time and the proportion alive at 1 year exceed that of prior reports involving large patient groups, possibly due to better patient selection.